Thursday, 15 March 2012

Miostat



carbachol

Dosage Form: intraocular solution
Miostat®

(CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%

DESCRIPTION


Miostat® (carbachol intraocular solution, USP) is a sterile balanced salt solution of carbachol for intraocular injection. The active ingredient is represented by the chemical structure:



Established name:


Carbachol


Chemical name:


Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,Ntrimethyl-, chloride.


Molecular Formula: C6H15CIN2O2


Molecular Weight: 182.65


Each mL contains: Active: carbachol 0.01%.


Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dihydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. pH range is 6.5-7.5.



CLINICAL PHARMACOLOGY


Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure. The exact mechanism by which carbachol lowers intraocular pressure is not precisely known.



INDICATIONS AND USAGE


Intraocular use for obtaining miosis during surgery. In addition, Miostat (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery.



CONTRAINDICATIONS


Should not be used in those persons showing hypersensitivity to any of the components of this preparation.



WARNINGS


For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease.



PRECAUTIONS


Use only if the container is undamaged.



Carcinogenesis


Studies in animals to evaluate the carcinogenic potential have not been conducted.



Pregnancy


Category C. There are no adequate and well-controlled studies in pregnant women. Miostat® (carbachol intraocular solution, USP) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers


It is not known if this medication is excreted in breast milk. Exercise caution when administering to a nursing woman.



Pediatric Use


Safety and efficacy in pediatric patients have not been established.



Geriatric Use


No overall differences in safety or effectiveness have been observed between elderly and younger patients.



ADVERSE REACTIONS


Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.


Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol.



DOSAGE AND ADMINISTRATION


Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.



HOW SUPPLIED


In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl stopper and aluminum seal packaged twelve to a carton.


NDC 0065-0023-15


STORAGE: Store at 15° - 30°C (59° - 86°F).


Rx Only


Alcon Laboratories, Inc.


Fort Worth, Texas 76134 USA


Printed in USA


© 2002, 2003 Alcon, Inc.


Revised: December 2003 340121-1203



PRINCIPAL DISPLAY PANEL


NDC 0065-0023-15


Miostat®


(CARBACHOL INTRAOCULAR


SOLUTION, USP) 0.01%


TWELVE


1.5 mL Sterile Glass Vials


Alcon®


Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA




    









Miostat 
carbachol  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0065-0023
Route of AdministrationOPHTHALMICDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CARBACHOL (CARBACHOL)CARBACHOL0.1 mg  in 1 mL






















Inactive Ingredients
Ingredient NameStrength
SODIUM CHLORIDE 
POTASSIUM CHLORIDE 
CALCIUM CHLORIDE 
MAGNESIUM CHLORIDE 
SODIUM ACETATE 
TRISODIUM CITRATE DIHYDRATE 
SODIUM HYDROXIDE 
HYDROCHLORIC ACID 
WATER 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10065-0023-1512 VIAL In 1 CARTONcontains a VIAL, GLASS
11.5 mL In 1 VIAL, GLASSThis package is contained within the CARTON (0065-0023-15)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01696804/15/1974


Labeler - Alcon Laboratories, Inc. (008018525)

Registrant - Alcon Laboratories, Inc. (008018525)









Establishment
NameAddressID/FEIOperations
Alcon Laboratories, Inc.008018525MANUFACTURE
Revised: 07/2011Alcon Laboratories, Inc.

More Miostat resources


  • Miostat Side Effects (in more detail)
  • Miostat Dosage
  • Miostat Use in Pregnancy & Breastfeeding
  • Miostat Drug Interactions
  • Miostat Support Group
  • 0 Reviews for Miostat - Add your own review/rating


  • Miostat Concise Consumer Information (Cerner Multum)

  • Miostat Ocular MedFacts Consumer Leaflet (Wolters Kluwer)

  • Carboptic Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Isopto Carbachol Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Miostat with other medications


  • Glaucoma
  • Intraocular Hypertension
  • Production of Miosis

Tuesday, 13 March 2012

Zodryl Dec 60



pseudoephedrine hydrochloride, codeine phosphate and guaifenesin

Dosage Form: oral suspension
Zodryl Dec 60 - codeine phosphate, guaifenesin and pseudoephedrine hydrochloride suspension

OTC - ACTIVE INGREDIENT


Codeine phosphate 1 mg/1mL: cough suppressant; Guaifenesin 20 mg/1mL: expectorant; Pseudoephedrine hydrochloride 4 mg/1mL: decongestant



PURPOSE


Temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you go to sleep; temporarily relieves nasal congestion due to a cold; temporarily restores freer breathing through the nose; helps loosen phlegm (mucus) and thin bronchial passageways of bothersome mucus and makes coughs more productive


Warnings



OTC - DO NOT USE


in children who have chronic pulmonary disease, shortness of breath, or such as occurs with asthma or if cough is accompanied by excessive phlegm (mucus) unless directed by a doctor; if taking a monoamine oxidase inhibitor (MAOI)



OTC - ASK DOCTOR


if your child has glaucoma, a breathing problem such as emphysema or chronic bronchitis, heart disease, high blood pressure, thyroid disease, diabetes.



OTC - ASK DOCTOR/PHARMACIST SECTION


if you or your child are taking sedatives or tranquilizers; if you or your child are taking prescription MAOI (certain drugs for depression, psychiatric, or emotional conditions), or for 2 weeks after stopping the MAOI drug.



OTC - WHEN USING THIS PRODUCT


do not exceed recommended dosage; may cause or aggravate constipation; if nervousness, dizziness, or sleepiness occur, discontinue use and consult a doctor



OTC - STOP USE AND ASK A DOCTOR IF


cough persists for more than 1 week, tends to recur, or is accompanied by a fever, rash, or persistent headache.  These could be signs of a serious condition.



OTC - KEEP THESE AND ALL DRUGS OUT OF REACH OF CHILDREN


In case of overdose, seek professional assistance for contact a Poison Control Center immediately.


Directions:



  • Take every 4-6 hours




  • Use only with enclosed calibrated oral dispenser




  • Do not take more than 4 doses in 24 hours or as directed by a doctor



Children 6 to under 12 years of age:  7.5mL


Other information store at controlled room temperature 20°-25°C (68°-77°F).


INACTIVE INGREDIENT


Bittermask, citric acid, FD& C blue #1, FD& C red #40, galloquinate, glycerin, grape flavor, magnesium aluminometasilicate, methylparaben, purified water, sodium citrate dihydrate, sucralose, xanthan gum



OTC – QUESTIONS SECTION


Call 1-866-574-8861 24 hours a day, 7 days a week.



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


Figure 1.  Primary Label- Front Page



Figure 2. Primary Label – Second Page



Figure 3. Primary Label – Last Page










Zodryl Dec 60 
codeine phosphate, guaifenesin and pseudoephedrine hydrochloride  suspension










Product Information
Product TypeHUMAN OTC DRUGNDC Product Code (Source)43378-125
Route of AdministrationORALDEA ScheduleCV    














Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PSEUDOEPHEDRINE HYDROCHLORIDE (PSEUDOEPHEDRINE)PSEUDOEPHEDRINE HYDROCHLORIDE30 mg  in 7.5 mL
CODEINE PHOSPHATE (CODEINE)CODEINE PHOSPHATE7.5 mg  in 7.5 mL
GUAIFENESIN (GUAIFENESIN)GUAIFENESIN150 mg  in 7.5 mL


























Inactive Ingredients
Ingredient NameStrength
ANHYDROUS CITRIC ACID 
FD&C BLUE NO. 1 
FD&C RED NO. 40 
TANNIC ACID 
GLYCERIN 
MAGNESIUM ALUMINUM SILICATE 
METHYLPARABEN 
WATER 
SODIUM CITRATE 
SUCRALOSE 
XANTHAN GUM 


















Product Characteristics
ColorpurpleScore    
ShapeSize
FlavorGRAPEImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
143378-125-08236 mL In 1 BOTTLE, PLASTICNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph finalpart34108/24/2009


Labeler - CodaDose, Inc. (831355115)

Registrant - Gorbec Pharmaceutical Services Inc. (791919678)









Establishment
NameAddressID/FEIOperations
Gorbec Pharmaceutical Services Inc.791919678manufacture
Revised: 08/2009CodaDose, Inc.




More Zodryl Dec 60 resources


  • Zodryl Dec 60 Side Effects (in more detail)
  • Zodryl Dec 60 Use in Pregnancy & Breastfeeding
  • Zodryl Dec 60 Drug Interactions
  • 0 Reviews for Zodryl Dec 60 - Add your own review/rating


Compare Zodryl Dec 60 with other medications


  • Cold Symptoms

aliskiren, amlodipine, and hydrochlorothiazide


Generic Name: aliskiren, amlodipine, and hydrochlorothiazide (AL is KYE ren, am LOE de peen, HYE droe klor oh THYE a zide)

Brand Names: Amturnide


What is aliskiren, amlodipine, and hydrochlorothiazide?

Aliskiren is an anti-hypertensive (blood pressure lowering) medication. It works by decreasing substances in the body that narrow blood vessels and raise blood pressure.


Amlodipine is in a group of drugs called calcium channel blockers. Amlodipine relaxes (widens) blood vessels and improves blood flow.


Hydrochlorothiazide is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention.


The combination of aliskiren, amlodipine, and hydrochlorothiazide is used to treat high blood pressure (hypertension).


Aliskiren, amlodipine, and hydrochlorothiazide is usually given after other blood pressure medications have been tried without successful treatment of symptoms.


Aliskiren, amlodipine, and hydrochlorothiazide may also be used for purposes not listed in this medication guide.


What is the most important information I should know about aliskiren, amlodipine, and hydrochlorothiazide?


Do not use this medication if you are pregnant. It could harm the unborn baby. Stop using this medication and tell your doctor right away if you become pregnant. You should not take this medication if you are allergic to aliskiren (Tekturna, Tekamlo), amlodipine (Norvasc, Caduet, Exforge, Lotrel, Tribenzor, Twynsta), hydrochlorothiazide (HCTZ, HydroDiuril, Hyzaar, Vaseretic, Zestoretic, and many others), or sulfa drugs (Bactrim, Septra, Sulfatrim, SMX-TMP, and others). You should not take aliskiren, amlodipine, and hydrochlorothiazide if you have severe kidney disease or are unable to urinate, or if you are also taking itraconazole (Sporanox) or cyclosporine (Gengraf, Neoral, Sandimmune).

Before you take aliskiren, amlodipine, and hydrochlorothiazide, tell your doctor if you have kidney or liver disease, glaucoma, lupus, asthma, congestive heart failure, angina (chest pain), coronary artery disease, an electrolyte imbalance (such as low potassium or magnesium), a penicillin allergy, if you are on a low-salt diet, or if you have ever had an allergic reaction to a blood pressure medication.


Your chest pain may become worse when you first start taking the medicine or when your dose is increased. Call your doctor if your chest pain is severe or ongoing. Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.

What should I discuss with my healthcare provider before taking aliskiren, amlodipine, and hydrochlorothiazide?


You should not take this medication if you are allergic to aliskiren (Tekturna, Tekamlo), amlodipine (Norvasc, Caduet, Exforge, Lotrel, Tribenzor, Twynsta), hydrochlorothiazide (HCTZ, HydroDiuril, Hyzaar, Vaseretic, Zestoretic, and many others), or sulfa drugs (Bactrim, Septra, Sulfatrim, SMX-TMP, and others). You should not take aliskiren, amlodipine, and hydrochlorothiazide if you have severe kidney disease or are unable to urinate, or if you are also taking itraconazole (Sporanox) or cyclosporine (Gengraf, Neoral, Sandimmune).

To make sure you can safely take aliskiren, amlodipine, and hydrochlorothiazide, tell your doctor if you have any of these other conditions:



  • kidney disease (or if you are on dialysis);




  • liver disease;




  • congestive heart failure;




  • angina (chest pain);




  • glaucoma;




  • systemic lupus erythematosus (SLE);




  • asthma;




  • coronary artery disease (hardened arteries);




  • an electrolyte imbalance (such as low levels of potassium or magnesium in your blood);




  • if you are allergic to penicillin;




  • if you are on a low-salt diet; or




  • if you have ever had an allergic reaction to a blood pressure medication.




FDA pregnancy category D. Do not use aliskiren, amlodipine, and hydrochlorothiazide if you are pregnant. Stop using this medication and tell your doctor right away if you become pregnant. This medication can cause injury or death to the unborn baby if you take the medicine during your second or third trimester. Use effective birth control while taking aliskiren, amlodipine, and hydrochlorothiazide. It is not known whether this medication passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are taking aliskiren, amlodipine, and hydrochlorothiazide.

How should I take aliskiren, amlodipine, and hydrochlorothiazide?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results.


Your chest pain may become worse when you first start taking the medicine or when your dose is increased. Call your doctor if your chest pain is severe or ongoing.

Aliskiren, amlodipine, and hydrochlorothiazide may be taken with or without food, but take it the same way each time.


While using aliskiren, amlodipine, and hydrochlorothiazide, you may need blood tests at your doctor's office. Your blood pressure will need to be checked often. Visit your doctor regularly.


If you need surgery, tell the surgeon ahead of time that you are using aliskiren, amlodipine, and hydrochlorothiazide.

Conditions that may cause very low blood pressure include: vomiting, diarrhea, heavy sweating, heart disease, dialysis, a low salt diet, or taking diuretics (water pills). Follow your doctor's instructions about the type and amount of liquids you should drink while taking aliskiren, amlodipine, and hydrochlorothiazide. Tell your doctor if you have a prolonged illness that causes diarrhea or vomiting.


Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life. Store in the original container at room temperature, away from moisture and heat.

See also: Aliskiren, amlodipine, and hydrochlorothiazide dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include rapid heartbeats, severe dizziness, warmth or tingly feeling, and fainting.


What should I avoid while taking aliskiren, amlodipine, and hydrochlorothiazide?


Do not use potassium supplements or salt substitutes while you are taking aliskiren, amlodipine, and hydrochlorothiazide, unless your doctor has told you to. Drinking alcohol can further lower your blood pressure and may increase certain side effects of aliskiren, amlodipine, and hydrochlorothiazide.

Avoid taking with foods that are high in fat, which can make it harder for your body to absorb aliskiren, amlodipine, and hydrochlorothiazide.


Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.

Aliskiren, amlodipine, and hydrochlorothiazide side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using aliskiren, amlodipine, and hydrochlorothiazide and call your doctor at once if you have a serious side effect such as:

  • swelling in your hands, ankles, or feet;




  • feeling like you might pass out;




  • vision problems, eye pain, or seeing halos around lights;




  • low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling);




  • high potassium (slow heart rate, weak pulse, muscle weakness, tingly feeling); or




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling.



Less serious side effects may include:



  • headache;




  • dizziness; or




  • stuffy nose, sore throat.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Aliskiren, amlodipine, and hydrochlorothiazide Dosing Information


Usual Adult Dose for Hypertension:

Initial dose: 1 tablet orally daily. The dosage may be increased after 2 weeks of therapy.

Maximum dose: Aliskiren/amlodipine/hydrochlorothiazide 300/10/25 mg orally daily.

Usual Geriatric Dose for Hypertension:

Patients greater than or equal to 75 years of age should start amlodipine at 2.5 mg, which is not available with aliskiren/amlodipine/hydrochlorothiazide.


What other drugs will affect aliskiren, amlodipine, and hydrochlorothiazide?


Tell your doctor about all other heart or blood pressure medications you are taking.


Before using aliskiren, amlodipine, and hydrochlorothiazide, tell your doctor if you regularly use other medicines that can lower blood pressure (such as sedatives, narcotic pain medicine, sleeping pills, and medicine for seizures or anxiety). They can add to the blood pressure lowering effects of aliskiren, amlodipine, and hydrochlorothiazide.

Tell your doctor about all other medicines you use, especially:



  • atorvastatin (Lipitor, Caduet);




  • cholestyramine (Questran) or colestipol (Colestid);




  • furosemide (Lasix);




  • irbesartan (Avapro);




  • lithium (Eskalith, Lithobid);




  • quinidine (Quin-G);




  • simvastatin (Zocor, Simcor, Vytorin, Juvisync);




  • tacrolimus (Prograf);




  • verapamil (Calan, Covera, Isoptin, Verelan);




  • insulin or oral diabetes medication;




  • an oral, nasal, inhaled, or injectable steroid medicine;




  • any other diuretic (water pill);




  • antifungal medication such as fluconazole (Diflucan), ketoconazole (Nizoral), miconazole (Oravig), or voriconazole (Vfend);




  • HIV or AIDS medications such as nelfinavir (Viracept), ritonavir (Norvir, Kaletra), or saquinavir (Invirase); or




  • non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others.



This list is not complete and other drugs may interact with aliskiren, amlodipine, and hydrochlorothiazide. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More aliskiren, amlodipine, and hydrochlorothiazide resources


  • Aliskiren, amlodipine, and hydrochlorothiazide Side Effects (in more detail)
  • Aliskiren, amlodipine, and hydrochlorothiazide Dosage
  • Aliskiren, amlodipine, and hydrochlorothiazide Use in Pregnancy & Breastfeeding
  • Aliskiren, amlodipine, and hydrochlorothiazide Drug Interactions
  • Aliskiren, amlodipine, and hydrochlorothiazide Support Group
  • 0 Reviews for Aliskiren, amlodipine, and hydrochlorothiazide - Add your own review/rating


Compare aliskiren, amlodipine, and hydrochlorothiazide with other medications


  • High Blood Pressure


Where can I get more information?


  • Your pharmacist can provide more information about aliskiren, amlodipine, and hydrochlorothiazide.

See also: aliskiren, amlodipine, and hydrochlorothiazide side effects (in more detail)


Sunday, 11 March 2012

Sulfac 10%


Generic Name: sulfacetamide ophthalmic (SUL fa SEET a mide off THAL mik)

Brand Names: Bleph-10, Ocu-Sul 10, Ocu-Sul 15, Ocu-Sul 30, Sodium Sulamyd, Sulf-10, Sulfac 10%


What is Sulfac 10% (sulfacetamide ophthalmic)?

Sulfacetamide ophthalmic is an antibiotic.


Sulfacetamide ophthalmic is used to treat bacterial infections of the eyes.


Sulfacetamide ophthalmic may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about Sulfac 10% (sulfacetamide ophthalmic)?


Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye.

Apply light pressure to the inside corner of your eye (near your nose) after each drop to prevent the fluid from draining down your tear ducts.


Who should not use Sulfac 10% (sulfacetamide ophthalmic)?


Do not use sulfacetamide ophthalmic if you have a viral or fungal infection in your eye. It is used to treat infections caused by bacteria only.

Do not use sulfacetamide ophthalmic if you have ever had an allergic reaction to a sulfa-based drug.


It is not known whether sulfacetamide ophthalmic will harm an unborn baby. Do not use sulfacetamide ophthalmic without first talking to your doctor if you are pregnant. It is also not known whether sulfacetamide ophthalmic passes into breast milk. Do not use sulfacetamide ophthalmic without first talking to your doctor if you are breast-feeding a baby.

How should I use Sulfac 10% (sulfacetamide ophthalmic)?


Use sulfacetamide ophthalmic eyedrops or ointment exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.


Wash your hands before using your eyedrops or ointment.


To apply the eye drops:



  • Shake the drops gently to be sure the medicine is well mixed. Tilt your head back slightly and pull down on your lower eyelid. Position the dropper above your eye. Look up and away from the dropper. Squeeze out a drop and close your eye. Apply gentle pressure to the inside corner of your eye (near your nose) for about 1 minute to prevent the liquid from draining down your tear duct. If you are using more than one drop in the same eye or drops in both eyes, repeat the process with about 5 minutes between drops.



To apply the ointment:



  • Hold the tube in your hand for a few minutes to warm it up so that the ointment comes out easily. Tilt your head back slightly and pull down gently on your lower eyelid. Apply a thin film of the ointment into your lower eyelid. Close your eye and roll your eyeball around in all directions for 1 to 2 minutes. If you are applying another eye medication, allow at least 10 minutes before the next application.




Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye. Do not use any eyedrop that is discolored or has particles in it. Store sulfacetamide ophthalmic at room temperature away from moisture and heat. Keep the bottle or tube properly capped.

What happens if I miss a dose?


Apply the missed dose as soon as you remember. However, if it is almost time for your next regularly scheduled dose, skip the missed dose and apply the next one as directed. Do not use a double dose of this medication.


What happens if I overdose?


An overdose of this medication is unlikely to occur. If you do suspect an overdose, wash the eye with water and call an emergency room or poison control center near you. If the drops or ointment have been ingested, drink plenty of fluid and call an emergency center for advice.


What should I avoid while using Sulfac 10% (sulfacetamide ophthalmic)?


Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye. Use caution when driving, operating machinery, or performing other hazardous activities. Sulfacetamide ophthalmic may cause blurred vision. If you experience blurred vision, avoid these activities.

If you wear contact lenses, ask your doctor if you should wear them during treatment with sulfacetamide ophthalmic. After applying the medication, wait at least 15 minutes before inserting contact lenses, unless otherwise directed by your doctor.


Do not use other eye drops or medications during treatment with sulfacetamide ophthalmic unless otherwise directed by your doctor.

Sulfac 10% (sulfacetamide ophthalmic) side effects


Serious side effects are not expected with this medication.


Commonly, some eye burning, stinging, irritation, itching, redness, blurred vision, eyelid itching, eyelid swelling, or sensitivity to light may occur.


This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Sulfac 10% (sulfacetamide ophthalmic)?


Do not use this medication with other eyedrops containing nitrates (e.g., silver nitrate).


Do not use other eye drops or medications during treatment with sulfacetamide ophthalmic unless otherwise directed by your doctor.

Drugs other than those listed here may also interact with sulfacetamide ophthalmic. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.



More Sulfac 10% resources


  • Sulfac 10% Side Effects (in more detail)
  • Sulfac 10% Use in Pregnancy & Breastfeeding
  • Sulfac 10% Drug Interactions
  • Sulfac 10% Support Group
  • 0 Reviews for Sulfac0% - Add your own review/rating


  • Bleph-10 Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Bleph-10 Prescribing Information (FDA)

  • Isopto Cetamide Prescribing Information (FDA)



Compare Sulfac 10% with other medications


  • Conjunctivitis
  • Trachoma


Where can I get more information?


  • Your pharmacist has additional information about sulfacetamide ophthalmic written for health professionals that you may read.

See also: Sulfac0% side effects (in more detail)


Saturday, 10 March 2012

permethrin topical


Generic Name: permethrin topical (per METH rin)

Brand names: Elimite, Lice Bedding Spray, Nix Complete Lice Treatment System, Nix Cream Rinse, Nix Lice Control, RID Home Lice Control Spray for Surfaces, ...show all 15 brand names.


What is permethrin topical?

Permethrin is an anti-parasite medication.


Permethrin topical (for the skin) is used to treat head lice and scabies.


Permethrin topical may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about permethrin topical?


Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.


Do not take this medication by mouth. It is for use only on the skin, hair, fabrics, or other surfaces. Do not apply permethrin topical to open cuts or wounds. Do not use this medication if you are allergic to permethrin or to chrysanthemums. For the most complete treatment of lice or scabies and to prevent reinfection, you must treat your environment (clothing, bedding, pillows, furniture, hats, hair brushes and accessories, etc) at the same time you treat your body.

Avoid sexual or intimate contact with others until your lice or scabies infection has cleared up. Avoid sharing hair brushes, combs, hair accessories, hats, clothing, bed linens, and other articles of personal use. Lice and scabies infections are highly contagious.


What should I discuss with my healthcare provider before using permethrin topical?


Do not use this medication if you are allergic to permethrin or to chrysanthemums. FDA pregnancy category B. Permethrin topical is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Permethrin can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on an infant younger than 2 months without the advice of a doctor.

How should I use permethrin topical?


Do not take this medication by mouth. It is for use only on the skin, hair, fabrics, or other surfaces.

Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.


You may need to shake the medication before each use. Follow the directions on the medicine label. Do not apply permethrin topical to open cuts or wounds.

To treat scabies:



  • Make sure your skin is clean and dry. Apply a thin layer of permethrin topical to all body parts from the neck down to the soles of the feet. Rub in completely. Leave the medication on for 8 to 14 hours, then wash it off completely.



  • When using permethrin topical on an infant, also apply the medication to the scalp, temples, and forehead. Avoid applying close to the eyes, nose, mouth, or genitals.


  • If your condition does not clear up within 14 days after applying permethrin topical, use another application.



To treat head lice:



  • When using the shampoo, apply it to dry hair only. Cover all hair completely and leave the shampoo in for 10 minutes. Then work into a lather using warm water and rinse out thoroughly.




  • When using the cream rinse, wash your hair using shampoo only (no conditioner or 2-in-1 shampoo). Rinse thoroughly and towel dry the hair, leaving it damp. Apply enough of the cream rinse to completely saturate all hair. Leave the cream rinse in your hair for 10 minutes.



  • Use a towel or washcloth to protect your eyes while the medication is left in your hair.


  • Use a second application if lice are still seen 7 days after your first treatment.




  • You may also use a nit comb to remove lice eggs from the hair. Your hair should be slightly damp while using a nit comb. Work on only one section of hair at a time, combing through 1- to 2-inch strands from the scalp to the ends.




  • Rinse the nit comb often during use. Place removed nits into a sealed plastic bag and throw it into the trash to prevent re-infestation.




  • Check the scalp again daily to make sure all nits have been removed.



To treat pubic lice (crabs):



  • Wash and dry the treatment area. Apply permethrin topical to all pubic hair and any surrounding hairs on the thighs and around the anus.




  • Avoid getting this medication inside the rectum or vagina.




  • Leave the medication in for 10 minutes. Then work into a lather using warm water and rinse out thoroughly.




  • You may also use a nit comb to remove lice eggs from pubic hair (hair should be slightly damp).




  • All sexual partners should also be treated to prevent re-infestation of crabs.




To prevent reinfection, wash all clothing, hats, bed clothes, bed linens, and towels in hot water and dry in high heat. Dry-clean any non-washable clothing. Hair brushes, combs, and hair accessories should be soaked in hot water for at least 10 minutes.

Use permethrin surface spray to disinfect non-washable items such as:



  • furniture;




  • mattresses and pillows;




  • stuffed toys;




  • hats, gloves, and scarves;




  • headphones or headbands;




  • the inside of a bike helmet; or




  • seats and carpets inside your car.



Stuffed toys or pillows that cannot be washed should be sealed in air-tight plastic bags for 4 weeks.


Vacuum all rugs and carpets and throw away the vacuum cleaner bag.


For the most complete treatment of lice or scabies, you must treat your environment (clothing, bedding, etc) at the same time you treat your body. Store permethrin topical at room temperature away from moisture and heat.

What happens if I miss a dose?


Since permethrin topical is usually needed only once, you are not likely to be on a dosing schedule. Wait at least 7 days before using a second application.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Symptoms of a permethrin topical overdose are unknown.


What should I avoid while using permethrin topical?


Avoid getting this medication in your mouth or eyes. If it does get into any of these areas, rinse with water.

Do not use other medicated skin products unless your doctor has told you to.


Avoid sexual or intimate contact with others until your lice or scabies infection has cleared up. Avoid sharing hair brushes, combs, hair accessories, hats, clothing, bed linens, and other articles of personal use. Lice and scabies infections are highly contagious.


Permethrin topical side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have severe burning, stinging, redness, or swelling after applying permethrin topical.

Less serious side effects may include:



  • itching or mild skin rash;




  • mild burning, stinging, or redness; or




  • numbness or tingling where the medication was applied.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Permethrin topical Dosing Information


Usual Adult Dose for Scabies:

Permethrin topical 5% cream:
Thoroughly massage into the skin from the neck to the soles of the feet. The cream should be removed by washing (shower or bath) after 8 to 14 hours.

Usual Adult Dose for Lice:

Permethrin topical 1% kit:
Apply lotion/creme rinse to shampooed and towel-dried hair until hair and scalp are saturated (especially behind the ears and on the nape of the neck). Leave on hair for 10 minutes and rinse with water. Use comb and/or gloves provided to remove remaining nits.

Permethrin topical 1% solution:
Apply to shampooed and towel-dried hair until hair and scalp are saturated (especially behind the ears and on the nape of the neck). Leave on hair for 10 minutes and rinse with water.

Usual Pediatric Dose for Scabies:

Permethrin topical 5% cream
Infants: Thoroughly massage along the hairline, neck, temple, and forehead. The cream should be removed by washing after 8 to 14 hours.

Usual Pediatric Dose for Lice:

Permethrin topical 1% kit:
2 months or older: Apply lotion/creme rinse to shampooed and towel-dried hair until hair and scalp are saturated (especially behind the ears and on the nape of the neck). Leave on hair for 10 minutes and rinse with water. Use comb and/or gloves provided to remove remaining nits.


What other drugs will affect permethrin topical?


It is not likely that other drugs you take orally or inject will have an effect on topically applied permethrin. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More permethrin topical resources


  • Permethrin topical Side Effects (in more detail)
  • Permethrin topical Use in Pregnancy & Breastfeeding
  • Permethrin topical Support Group
  • 2 Reviews for Permethrin - Add your own review/rating


  • Acticin Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Acticin Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Elimite Prescribing Information (FDA)



Compare permethrin topical with other medications


  • Head Lice
  • Lice
  • Scabies


Where can I get more information?


  • Your pharmacist has additional information about permethrin topical written for health professionals that you may read.

See also: permethrin side effects (in more detail)


Saturday, 3 March 2012

Easyhaler Salbutamol 200mcg





1. Name Of The Medicinal Product



Easyhaler Salbutamol Sulphate 200 micograms per actuation inhalation powder


2. Qualitative And Quantitative Composition



Metered dose delivery 200 mcg of Salbutamol per actuation as Salbutamol Sulphate Ph.Eur.



3. Pharmaceutical Form



White or almost white odourless powder intended for respiratory use by oral inhalation.



4. Clinical Particulars



4.1 Therapeutic Indications



Symptomatic treatment of acute asthma attack. Prevention of exercise-induced bronchospasm. Symptomatic treatment of broncho-asthma and other conditions associated with reversible airways obstruction.



Salbutamol provides a short-acting bronchodilation with fast onset of action in reversible airways obstruction due to asthma.



Easyhaler Salbutamol Sulphate should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an attack (e.g. before exercise or unavoidable allergen exposure).



Salbutamol is valuable as a rescue medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.



4.2 Posology And Method Of Administration



The preparation is intended for oral inhalation only.



This preparation is particularly useful for patients unable to use metered dose inhalers properly and for patients to whom the use of an inhalation aerosol causes irritation of airways. The lowest effective doses of inhaled Salbutamol are recommended to be used in the treatment of asthma. In long term treatment, it is recommended instead of continual use, to use inhaled Salbutamol only when needed.



Adults and Elderly:



For the relief of acute bronchospasm and for managing intermittent episodes of asthma one inhalation (200 micrograms) may be administered as a single starting dose, this may be increased to two inhalations (400 micrograms).



To prevent exercise-induced bronchospasm or allergen bronchospasm one inhalations (200 micrograms) should be taken before challenge, this dose (200 micrograms) may be repeated if necessary.



Children :



One inhalation (200 micrograms) is the recommended starting dose for the relief of acute bronchospasm, or before exercise or allergen exposure.



On demand use of Easyhaler Salbutamol Sulphate should not exceed four inhalations (800 micrograms) in any 24 hour period.



For optimum results in most patients Easyhaler Salbutamol Sulphate inhaler should be used regularly during asthmatic attacks. The bronchodilator effect of each administration of inhaled salbutamol lasts for four hours, except in patients whose asthma is becoming worse. Such patients should be warned not to increase their usage of salbutamol, but should seek medical advice in case treatment with an inhaled and/or systemic glucocorticosteroid is indicated.



4.3 Contraindications



A history of hypersensitivity to any components of the product. Intravenous or oral salbutamol is used for the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, however inhaled salbutamol is not appropriate for management of premature labour.



Salbutamol preparations should not be used for threatened abortion.



4.4 Special Warnings And Precautions For Use



Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment including lung function testing as the patients are at risk of severe attacks and even death. Physicians should consider using oral corticosteroid therapy or the maximum use of inhaled corticosteroids. Increasing use of bronchodilators, particularly short-acting inhaled ß2-agonists to relieve symptoms indicates deteriorating asthma control (especially if the peak expiratory flow rate value falls and/or becomes irregular).



In the event of a previous effective dose of inhaled salbutamol failing to give relief for at least three hours or if they need more inhalations than usual, the patient should be advised to seek medical advice as soon as possible. In this situation patients should be reassessed and consideration given to an increase in their anti-inflammatory therapy, (e.g. higher doses of inhaled corticosteroids or a course of oral corticosteroids). A regular anti-inflammatory controller medication taken on a daily basis is required as soon as the patient needs inhaled Beta2-agonists more than once a week. Severe episodes of asthma must be treated in the normal way.



As there may be adverse effects associated with excessive dosing, the dosage and frequency of administration should only be increased on medical advice.



Salbutamol should be administered with caution in patients with thyrotoxicosis, cardiac insufficiency, hypokalaemia, myocardial ischaemia, tachyarrhythmia and hypertrophic obstructive cardiomyopathy.



Potentially serious hypokalaemia may result from ß2-agonist therapy, mainly from parenteral and nebulised therapy. Particular caution is advised in acute severe asthma, as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.



Rarely inhalation therapy may cause bronchospasm after dosing. In this event, treatment with Salbutamol must be immediately discontinued and, if need be, replaced with another therapy.



Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.



One dose contains less than 10 mg lactose, which probably does not cause symptoms in lactose intolerant patients. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Concomitant administration of salbutamol and non-selective ß -blocking drugs such as Propranolol is not recommended.



Patients treated with monoamine oxidase inhibitors or tricyclic antidepressants should be followed clinically in the beginning of salbutamol treatment, because the action of salbutamol on the vascular system may be potentiated.



4.6 Pregnancy And Lactation



Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus. Salbutamol has been in widespread use for many years in human beings without apparent ill consequences; this includes its well established use in the management of premature labour. However, as with the majority of drugs, there is little published evidence of its safety in the early stages of human pregnancy, but in animal studies there is evidence of some harmful effects on the foetus at very high doses.



As salbutamol is probably excreted in breast milk, its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother outweighs any potential risk to the neonate.



4.7 Effects On Ability To Drive And Use Machines



None Known.



4.8 Undesirable Effects



The undesirable effects caused by normally used inhaled doses of Salbutamol are mild, typical for sympathomimetic agents, and they usually disappear with continued treatment.



Frequencies are defined as: very common (>1/10), common, (>1/100 and <1/10), uncommon (>1/1000 and <1/100), rare (>1/10,000 and <1/1000), very rare (<1/10,000) and not known (cannot be estimated from available data).












































 



 




Common




Uncommon




Rare




Very Rare




Immune System disorders




 




hypersensitivity reactions (angioedema, urticaria, hypotension and collapse)




 



 


Metabolism and nutrition disorders




 




 



 




hypokalaemia




 



 




Nervous system disorders:




 




Headache




hyperactivity, restlessness, dizziness



 


Cardiac disorders




palpitations



 

 


myocardial ischaemia



Cardiac arrhytmias including atrial fibrilation, supraventricular tachycardia and extrasystoles




Vascular disorders




peripheral vasodilatation, and as a result small increase in heart rate



 

 

 


Respiratory, thoracic and mediastinal disorders




 



 


bronchospasm (see section 4.4), cough, irritation of mouth and throat which may be prevented by rinsing the mouth after inhalation.



 


Musculoskeletal and connective tissue and bone disorders:




tremor



 


muscle cramps,



 


4.9 Overdose



Excess repeat use of inhalations may produce adverse effects such as tachycardia, CNS stimulation, tremor, hypokalaemia and hyperglycaemia.



Treatment consists of discontinuation of salbutamol together with appropriate symptomatic therapy. The preferred antidote for overdosage with salbutamol is a cardioselective beta-blocking agent, but beta-blocking drugs should be used with caution in patients with a history of bronchospasm. Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored. If hypokalaemia occurs potassium replacement via the oral route should be given. In patients with severe hypokalaemia intravenous replacement may be necessary.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Salbutamol is a selective ß 2-adrenergic receptor agonist. The pharmacological effects of salbutamol are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3',5',-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Salbutamol also stimulates mucous secretion and mucociliary transport in the respiratory tract. Bronchial effects of inhaled salbutamol can be detected after a few minutes and duration of action is normally 4-6 hours.



Like other ß 2-adrenoceptor agonists salbutamol also has cardiovascular effects in some patients as measured by changes in pulse rate, blood pressure, symptoms and ECG changes. These effects can especially be detected after oral and intravenous administration of salbutamol. Furthermore oral and intravenous salbutamol causes reduction in uterine tonicity which has been associated with pain relief in pregnancy. In addition, salbutamol has some metabolic effects. Especially intravenous and nebulised salbutamol decreases serum potassium concentrations although the effect is generally mild and transient. Salbutamol has also lipolytic effects and it has been shown to cause increases in blood glucose and insulin probably by stimulating glycogenolysis and having a stimulatory effect on ß 2-receptors in pancreas cells.



5.2 Pharmacokinetic Properties



Orally administered salbutamol is well absorbed with peak plasma concentrations occurring 1 to 4 hours after administration. The major proportion of inhaled Salbutamol is swallowed. The fraction that is distributed to the lung (approx. 10-25%) is rapidly seen in the circulation as free unmetabolised drug. The plasma concentrations of inhaled Salbutamol are, however, lower than those produced by usual oral doses.



Salbutamol and its metabolites are rapidly excreted in the urine and faeces with about 80% of the dose being recovered in urine within 24 hours. The elimination half-life of Salbutamol is 2.7 - 5.5 hours after oral and inhaled administration.



5.3 Preclinical Safety Data



The short term toxicity has been tested in different animal species - the mouse, the rat and the dog - at doses extending to several thousand fold higher than the intended human therapeutic dose - maximally in the region of 15 µg/kg daily. The lethal doses via the intravenous route in the rodents range from 50mg/kg, via the peroral route to around 2000 mg/kg and even higher. Thus the agent exhibits low acute systemic toxicity.



Local toxicity on the airway has not been exclusively studied, but the historical evidence based on long clinical use suggests good airway tolerance.



The subacute toxic effects on the cardiac muscle are seen at doses ranging from 0.2 to 3mg/kg. This is a manifestation of the pharmacodynamics of salbutamol at grossly elevated doses.



The doses administered in subchronic toxicity studies have been in the milligram ranges per kilogram - 0.15 to 50 - via the oral route or by inhalation. The species have been the rat (p.o. administration), and the dog (p.o. and inhalation). The toxic signs and symptoms exhibited were, as noted in the paragraph above, related to the mode of action on the adrenergic receptor.



The chronic toxicity, again, is manifested as exaggerated pharmacodynamic effects in animals.



Animal data on reproductive toxicity is quite limited. Sympathomimetics, including salbutamol, are widely used in clinical medicine in patients of fertile age. In spite of this fact, no adverse reproductive effects attributable to salbutamol are reported in the literature.



Embryotoxicity in animal studies seems to be related only to the mouse. In this species the union of the flat bones of the lower part of the skull seem to be involved. The specific mechanism of this has not been fully elucidated.



Foetal toxicity at high single or elevated chronic doses are related to energy metabolism from glycogen. Catecholamines liberate energy in the form of glucose from glycogen stored in liver and muscle. This action is mediated by glycogen synthase and phosphorylase of these tissues. Elevated foetal insulin and glucose levels suggest a higher sensitivity of the foetal pancreas to this stimulation of ß -adrenergic receptors.



The classic airways of mutagenic potential by which this agent has been tested have exhibited no increase in the incidence of mutations.



The potential of increase in the number of neoplasms shows a species and even a strain specificity, as did the effect on the delay in union flat jaw bones. Ovarian leiomyomas, benign tumours of smooth muscle, occur with a significantly higher frequency in the rat, particularly of the Spraque-Dawley strain. The other rodent species do not appear to be affected, suggesting a difference in the susceptibility of the uterine muscle of Spraque-Dawley to ß -adrenergic stimulation.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Lactose Ph.Eur.



6.2 Incompatibilities



None



6.3 Shelf Life



Unopened: 3 years.



After first opening of foil pouch: 6 months.



6.4 Special Precautions For Storage



Store in a dry place at a temperature not exceeding 25°C



6.5 Nature And Contents Of Container



The multidose powder inhaler (Easyhaler) consists of seven plastic parts and a stainless steel spring.



The plastic materials of the inhaler are polyester, LDPE, polycarbonate, acetal, styrene butadiene, polypropylene.



The inhaler is wrapped in laminate foil and packed in a cardboard box.



The starting package contains an inhaler and a protective cover. The maintenance pack contains the dry powder inhaler only.



Pack size: 200 actuations.



6.6 Special Precautions For Disposal And Other Handling



Patients are instructed to perform a rapid and forced inhalation through the Easyhaler device. Patients are instructed not to exhale into the device. illustrated instructions for use accompany each package.



7. Marketing Authorisation Holder



Orion Corporation,



Orionintie 1,



FIN-02200 Espoo,



Finland.



8. Marketing Authorisation Number(S)



PL27925/0003



9. Date Of First Authorisation/Renewal Of The Authorisation



2 June 1998/ 1 June 2003



10. Date Of Revision Of The Text



2 March 2010




Wednesday, 29 February 2012

Idamycin PFS



idarubicin hydrochloride

Dosage Form: injection solution
Idamycin PFS®

idarubicin hydrochloride injection

Rx only


FOR INTRAVENOUS USE ONLY


Warnings
  1. Idamycin PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration.

  2. As is the case with other anthracyclines the use of Idamycin PFS can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre-existing cardiac disease.

  3. As is usual with antileukemic agents, severe myelosuppression occurs when Idamycin PFS is used at effective therapeutic doses.

  4. It is recommended that Idamycin PFS be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.

  5. Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.)



Idamycin PFS Description


Idamycin PFS Injection contains idarubicin hydrochloride and is a sterile, semi-synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12- Naphthacenedione, 9 - acetyl - 7 - [(3 - amino - 2,3,6 - trideoxy - α - L - lyxo - hexopyranosyl)oxy] - 7,8,9,10 - tetrahydro - 6,9,11 - trihydroxyhydrochloride, (7S-cis). The structural formula is as follows:



Idamycin PFS is a sterile, red-orange, isotonic parenteral preservative-free solution, available in 5 mL (5 mg), 10 mL (10 mg) and 20 mL (20 mg) single-use-only vials.


Each mL contains Idarubicin HCl, USP 1 mg and the following inactive ingredients: Glycerin, USP 25 mg and Water for Injection, USP q.s. Hydrochloric Acid, NF is used to adjust the pH to a target of 3.5.



Idamycin PFS - Clinical Pharmacology



Mechanism of Action


Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. The absence of a methoxy group at position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with other anthracyclines.



Pharmacokinetics


General Pharmacokinetics

Pharmacokinetic studies have been performed in adult leukemia patients with normal renal and hepatic function following intravenous administration of 10 to 12 mg/m2 of idarubicin daily for 3 to 4 days as a single agent or combined with cytarabine. The plasma concentrations of idarubicin are best described by a two or three compartment open model. The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine. The elimination of the primary active metabolite, idarubicinol, is considerably slower than that of the parent drug with an estimated mean terminal half-life that exceeds 45 hours; hence, its plasma levels are sustained for a period greater than 8 days.


Distribution

The disposition profile shows a rapid distributive phase with a very high volume of distribution presumably reflecting extensive tissue binding. Studies of cellular (nucleated blood and bone marrow cells) drug concentrations in leukemia patients have shown that peak cellular idarubicin concentrations are reached a few minutes after injection. Concentrations of idarubicin and idarubicinol in nucleated blood and bone marrow cells are more than a hundred times the plasma concentrations. Idarubicin disappearance rates in plasma and cells were comparable with a terminal half-life of about 15 hours. The terminal half-life of idarubicinol in cells was about 72 hours. The extent of drug and metabolite accumulation predicted in leukemia patients for Days 2 and 3 of dosing, based on the mean plasma levels and half-life obtained after the first dose, is 1.7- and 2.3-fold, respectively, and suggests no change in kinetics following a daily × 3 regimen. The percentages of idarubicin and idarubicinol bound to human plasma proteins averaged 97% and 94%, respectively, at concentrations similar to maximum plasma levels obtained in the pharmacokinetic studies. The binding is concentration independent. The plasma clearance is twice the expected hepatic plasma flow indicating extensive extrahepatic metabolism.


Metabolism

The primary active metabolite formed is idarubicinol. As idarubicinol has cytotoxic activity, it presumably contributes to the effects of idarubicin.


Elimination

The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.



Pharmacokinetics in Special Populations


Pediatric Patients

Idarubicin studies in pediatric leukemia patients, at doses of 4.2 to 13.3 mg/m2/day × 3, suggest dose independent kinetics. There is no difference between the half-lives of the drug following daily × 3 or weekly × 3 administration. Cerebrospinal fluid (CSF) levels of idarubicin and idarubicinol were measured in pediatric leukemia patients treated intravenously. Idarubicin was detected in 2 of 21 CSF samples (0.14 and 1.57 ng/mL), while idarubicinol was detected in 20 of these 21 CSF samples obtained 18 to 30 hours after dosing (mean = 0.51 ng/mL; range, 0.22 to 1.05 ng/mL). The clinical relevance of these findings is unknown.


Hepatic and Renal Impairment

The pharmacokinetics of idarubicin have not been evaluated in leukemia patients with hepatic impairment. It is expected that in patients with moderate or severe hepatic dysfunction, the metabolism of idarubicin may be impaired and lead to higher systemic drug levels. The disposition of idarubicin may be also affected by renal impairment. Therefore, a dose reduction should be considered in patients with hepatic and/or renal impairment (see DOSAGE AND ADMINISTRATION).



Drug-Drug Interactions


No formal drug interaction studies have been performed.



Clinical Studies


Four prospective randomized studies, three U.S. and one Italian, have been conducted to compare the efficacy and safety of idarubicin (IDR) to that of daunorubicin (DNR), each in combination with cytarabine as induction therapy in previously untreated adult patients with acute myeloid leukemia (AML). These data are summarized in the following table and demonstrate significantly greater complete remission rates for the IDR regimen in two of the three U.S. studies and significantly longer overall survival for the IDR regimen in two of the three U.S. studies.
























































Induction* Regimen Dose in mg/m2-

Daily × 3 Days
Complete Remission Rate,

All Pts Randomized
Median Survival

(Days)

All Pts Randomized
IDRDNRIDRDNRIDRDNR

*

Patients who had persistent leukemia after the first induction course received a second course

†

Memorial Sloan Kettering Cancer Center

‡

Cytarabine 25 mg/m2 bolus IV followed by 200 mg/m2 daily × 5 days by continuous infusion

§

Overall p < 0.05, unadjusted for prognostic factors or multiple endpoints


Southeastern Cancer Study Group

#

Cytarabine 100 mg/m2 daily × 7 days by continuous infusion

Þ

Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto

U.S. (IND Studies)
1. MSKCC†

   (Age ≤ 60 years)
12‡50‡51/65§

(78%)
38/65

(58%)
508§435
2. SEG

   (Age ≥ 15 years)
12#45#76/111§

(69%)
65/119

(55%)
328277
3. U.S. Multicenter

   (Age ≥ 18 years)
13#45#68/101

(67%)
66/113

(58%)
393§281
Foreign (non-IND study)
   GIMEMAÞ

   (Age ≥ 55 years)
12#45#49/124

(40%)
49/125

(39%)
87169

There is no consensus regarding optional regimens to be used for consolidation; however, the following consolidation regimens were used in U.S. controlled trials. Patients received the same anthracycline for consolidation as was used for induction.


Studies 1 and 3 utilized 2 courses of consolidation therapy consisting of idarubicin 12 or 13 mg/m2 daily for 2 days, respectively (or DNR 50 or 45 mg/m2 daily for 2 days), and cytarabine, either 25 mg/m2 by IV bolus followed by 200 mg/m2 daily by continuous infusion for 4 days (Study 1), or 100 mg/m2 daily for 5 days by continuous infusion (Study 3). A rest period of 4 to 6 weeks is recommended prior to initiation of consolidation and between the courses. Hematologic recovery is mandatory prior to initiation of each consolidation course.


Study 2 utilized 3 consolidation courses, administered at intervals of 21 days or upon hematologic recovery. Each course consisted of idarubicin 15 mg/m2 IV for 1 dose (or DNR 50 mg/m2 IV for 1 dose), cytarabine 100 mg/m2 every 12 hours for 10 doses and 6-thioguanine 100 mg/m2 orally for 10 doses. If severe myelosuppression occurred, subsequent courses were given with 25% reduction in the doses of all drugs. In addition, this study included 4 courses of maintenance therapy (2 days of the same anthracycline as was used in induction and 5 days of cytarabine).


Toxicities and duration of aplasia were similar during induction on the 2 arms in the U.S. studies except for an increase in mucositis on the IDR arm in one study. During consolidation, duration of aplasia on the IDR arm was longer in all three studies and mucositis was more frequent in two studies. During consolidation, transfusion requirements were higher on the IDR arm in the two studies in which they were tabulated, and patients on the IDR arm in Study 3 spent more days on IV antibiotics (Study 3 used a higher dose of idarubicin).


The benefit of consolidation and maintenance therapy in prolonging the duration of remission and survival is not proven.


Intensive maintenance with idarubicin is not recommended in view of the considerable toxicity (including deaths in remission) experienced by patients during the maintenance phase of Study 2.


A higher induction death rate was noted in patients on the IDR arm in the Italian trial. Since this was not noted in patients of similar age in the U.S. trials, one may speculate that it was due to a difference in the level of supportive care.



Indications and Usage for Idamycin PFS


Idamycin PFS Injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.



Warnings


Idarubicin is intended for administration under the supervision of a physician who is experienced in leukemia chemotherapy.


Idarubicin is a potent bone marrow suppressant. Idarubicin should not be given to patients with pre-existing bone marrow suppression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk.


Severe myelosuppression will occur in all patients given a therapeutic dose of this agent for induction, consolidation or maintenance. Careful hematologic monitoring is required. Deaths due to infection and/or bleeding have been reported during the period of severe myelosuppression. Facilities with laboratory and supportive resources adequate to monitor drug tolerability and protect and maintain a patient compromised by drug toxicity should be available. It must be possible to treat rapidly and completely a severe hemorrhagic condition and/or a severe infection.


Pre-existing heart disease and previous therapy with anthracyclines at high cumulative doses or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity and the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with idarubicin.


Myocardial toxicity as manifested by potentially fatal congestive heart failure, acute life-threatening arrhythmias or other cardiomyopathies may occur following therapy with idarubicin. Appropriate therapeutic measures for the management of congestive heart failure and/or arrhythmias are indicated.


Cardiac function should be carefully monitored during treatment in order to minimize the risk of cardiac toxicity of the type described for other anthracycline compounds. The risk of such myocardial toxicity may be higher following concomitant or previous radiation to the mediastinal-pericardial area or in patients with anemia, bone marrow depression, infections, leukemic pericarditis and/or myocarditis. While there are no reliable means for predicting congestive heart failure, cardiomyopathy induced by anthracyclines is usually associated with a decrease of the left ventricular ejection fraction (LVEF) from pretreatment baseline values.


Since hepatic and/or renal function impairment can affect the disposition of idarubicin, liver and kidney function should be evaluated with conventional clinical laboratory tests (using serum bilirubin and serum creatinine as indicators) prior to and during treatment. In a number of Phase III clinical trials, treatment was not given if bilirubin and/or creatinine serum levels exceeded 2 mg%. However, in one Phase III trial, patients with bilirubin levels between 2.6 and 5 mg% received the anthracycline with a 50% reduction in dose. Dose reduction of idarubicin should be considered if the bilirubin and/or creatinine levels are above the normal range. (See DOSAGE AND ADMINISTRATION.)



Pregnancy Category D


Idarubicin was embryotoxic and teratogenic in the rat at a dose of 1.2 mg/m2/day or one tenth the human dose, which was nontoxic to dams. Idarubicin was embryotoxic but not teratogenic in the rabbit even at a dose of 2.4 mg/m2/day or two tenths the human dose, which was toxic to dams. There is no conclusive information about idarubicin adversely affecting human fertility or causing teratogenesis. There has been one report of a fetal fatality after maternal exposure to idarubicin during the second trimester.


There are no adequate and well-controlled studies in pregnant women. If idarubicin is to be used during pregnancy, or if the patient becomes pregnant during therapy, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid pregnancy.



Precautions



General


Therapy with idarubicin requires close observation of the patient and careful laboratory monitoring. Hyperuricemia secondary to rapid lysis of leukemic cells may be induced. Appropriate measures must be taken to prevent hyperuricemia and to control any systemic infection before beginning therapy.


Extravasation of idarubicin can cause severe local tissue necrosis. Extravasation may occur with or without an accompanying stinging or burning sensation even if blood returns well on aspiration of the infusion needle. If signs or symptoms of extravasation occur the injection or infusion should be terminated immediately and restarted in another vein. (See DOSAGE AND ADMINISTRATION.)



Laboratory Tests


Frequent complete blood counts and monitoring of hepatic and renal function tests are recommended.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Formal long-term carcinogenicity studies have not been conducted with idarubicin. Idarubicin and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models (including bacterial systems, mammalian cells in culture and female Sprague-Dawley rats).


In male dogs given 1.8 mg/m2/day 3 times/week (about one seventh the weekly human dose on a mg/m2 basis) for 13 weeks, or 3 times the human dose, testicular atrophy was observed with inhibition of spermatogenesis and sperm maturation with few or no mature sperm. These effects were not readily reversed after a recovery of 8 weeks.



Pregnancy Category D


(See WARNINGS.)



Nursing Mothers


It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from idarubicin, mothers should discontinue nursing prior to taking this drug.



Pediatric Use


Safety and effectiveness in children have not been established.



Geriatric Use


Patients over 60 years of age who were undergoing induction therapy experienced congestive heart failure, serious arrhythmias, chest pain, myocardial infarction, and asymptomatic declines in LVEF more frequently than younger patients (see ADVERSE REACTIONS).



Adverse Reactions


Approximately 550 patients with AML have received idarubicin in combination with cytarabine in controlled clinical trials worldwide. In addition, over 550 patients with acute leukemia have been treated in uncontrolled trials utilizing idarubicin as a single agent or in combination. The table below lists the adverse experiences reported in U.S. Study 2 (see CLINICAL STUDIES) and is representative of the experiences in other studies. These adverse experiences constitute all reported or observed experiences, including those not considered to be drug related. Patients undergoing induction therapy for AML are seriously ill due to their disease, are receiving multiple transfusions, and concomitant medications including potentially toxic antibiotics and antifungal agents. The contribution of the study drug to the adverse experience profile is difficult to establish.


























































Induction PhasePercentage of Patients
IDRDNR
Adverse Experiences(N=110)(N=118)
Infection95%97%
Nausea & Vomiting82%80%
Hair Loss77%72%
Abdominal Cramps/Diarrhea73%68%
Hemorrhage63%65%
Mucositis50%55%
Dermatologic46%40%
Mental Status41%34%
Pulmonary-Clinical39%39%
Fever (not elsewhere classified)26%28%
Headache20%24%
Cardiac-Clinical16%24%
Neurologic-Peripheral Nerves7%9%
Pulmonary Allergy2%4%
Seizure4%5%
Cerebellar4%4%

The duration of aplasia and incidence of mucositis were greater on the IDR arm than the DNR arm, especially during consolidation in some U.S. controlled trials (see CLINICAL STUDIES).


The following information reflects experience based on U.S. controlled clinical trials.



Myelosuppression


Severe myelosuppression is the major toxicity associated with idarubicin therapy, but this effect of the drug is required in order to eradicate the leukemic clone. During the period of myelosuppression, patients are at risk of developing infection and bleeding which may be life-threatening or fatal.



Gastrointestinal


Nausea and/or vomiting, mucositis, abdominal pain and diarrhea were reported frequently, but were severe (equivalent to WHO Grade 4) in less than 5% of patients. Severe enterocolitis with perforation has been reported rarely. The risk of perforation may be increased by instrumental intervention. The possibility of perforation should be considered in patients who develop severe abdominal pain and appropriate steps for diagnosis and management should be taken.



Dermatologic


Alopecia was reported frequently and dermatologic reactions including generalized rash, urticaria and a bullous erythrodermatous rash of the palms and soles have occurred. The dermatologic reactions were usually attributed to concomitant antibiotic therapy. Local reactions including hives at the injection site have been reported. Recall of skin reaction due to prior radiotherapy has occurred with idarubicin administration.



Hepatic and Renal


Changes in hepatic and renal function tests have been observed. These changes were usually transient and occurred in the setting of sepsis and while patients were receiving potentially hepatotoxic and nephrotoxic antibiotics and antifungal agents. Severe changes in renal function (equivalent to WHO Grade 4) occurred in no more than 1% of patients, while severe changes in hepatic function (equivalent to WHO Grade 4) occurred in less than 5% of patients.



Cardiac


Congestive heart failure (frequently attributed to fluid overload), serious arrhythmias including atrial fibrillation, chest pain, myocardial infarction and asymptomatic declines in LVEF have been reported in patients undergoing induction therapy for AML. Myocardial insufficiency and arrhythmias were usually reversible and occurred in the setting of sepsis, anemia and aggressive intravenous fluid administration. The events were reported more frequently in patients over age 60 years and in those with pre-existing cardiac disease.



Overdosage


There is no known antidote to idarubicin. Two cases of fatal overdosage in patients receiving therapy for AML have been reported. The doses were 135 mg/m2 over 3 days and 45 mg/m2 of idarubicin and 90 mg/m2 of daunorubicin over a three day period.


It is anticipated that overdosage with idarubicin will result in severe and prolonged myelosuppression and possibly in increased severity of gastrointestinal toxicity. Adequate supportive care including platelet transfusions, antibiotics and symptomatic treatment of mucositis is required. The effect of acute overdose on cardiac function is not fully known, but severe arrhythmia occurred in 1 of the 2 patients exposed. It is anticipated that very high doses of idarubicin may cause acute cardiac toxicity and may be associated with a higher incidence of delayed cardiac failure.


Disposition studies with idarubicin in patients undergoing dialysis have not been carried out. The profound multicompartment behavior, extensive extravascular distribution and tissue binding, coupled with the low unbound fraction available in the plasma pool make it unlikely that therapeutic efficacy or toxicity would be altered by conventional peritoneal or hemodialysis.



Idamycin PFS Dosage and Administration


(See WARNINGS)


For induction therapy in adult patients with AML the following dose schedule is recommended:


Idamycin PFS Injection 12 mg/m2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. The cytarabine may be given as 100 mg/m2 daily by continuous infusion for 7 days or as cytarabine 25 mg/m2 intravenous bolus followed by cytarabine 200 mg/m2 daily for 5 days continuous infusion. In patients with unequivocal evidence of leukemia after the first induction course, a second course may be administered. Administration of the second course should be delayed in patients who experience severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended. In patients with hepatic and/or renal impairment, a dose reduction of Idamycin PFS should be considered. Idamycin PFS should not be administered if the bilirubin level exceeds 5 mg%. (See WARNINGS.)


The benefit of consolidation in prolonging the duration of remissions and survival is not proven. There is no consensus regarding optional regimens to be used for consolidation. (See CLINICAL STUDIES for doses used in U.S. Clinical studies.)



Preparation and Administration Precautions


Caution in handling the solution must be exercised as skin reactions associated with Idamycin PFS may occur. Skin accidentally exposed to Idamycin PFS should be washed thoroughly with soap and water and if the eyes are involved, standard irrigation techniques should be used immediately. The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.


Care in the administration of Idamycin PFS will reduce the chance of perivenous infiltration. It may also decrease the chance of local reactions such as urticaria and erythematous streaking. During intravenous administration of Idamycin PFS extravasation may occur with or without an accompanying stinging or burning sensation even if blood returns well on aspiration of the infusion needle. If any signs or symptoms of extravasation have occurred, the injection or infusion should be immediately terminated and restarted in another vein. If it is known or suspected that subcutaneous extravasation has occurred, it is recommended that intermittent ice packs (1/2 hour immediately, then 1/2 hour 4 times per day for 3 days) be placed over the area of extravasation and that the affected extremity be elevated. Because of the progressive nature of extravasation reactions, the area of injection should be frequently examined and plastic surgery consultation obtained early if there is any sign of a local reaction such as pain, erythema, edema or vesication. If ulceration begins or there is severe persistent pain at the site of extravasation, early wide excision of the involved area should be considered.


Idamycin PFS should be administered slowly (over 10 to 15 minutes) into the tubing of a freely running intravenous infusion of Sodium Chloride Injection, USP (0.9%) or 5% Dextrose Injection, USP. The tubing should be attached to a Butterfly needle or other suitable device and inserted preferably into a large vein.


Incompatibility

Unless specific compatibility data are available, Idamycin PFS should not be mixed with other drugs. Precipitation occurs with heparin. Prolonged contact with any solution of an alkaline pH will result in degradation of the drug.


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and containers permit.


Handling and Disposal

Procedures for handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.



How is Idamycin PFS Supplied


Idamycin PFS Injection (idarubicin hydrochloride injection)


Single Dose Glass Vials: Sterile single use only, contains no preservative.


NDC 0013-2200-01 5 mg/5 mL vial (1 mg/mL), single vials.


NDC 0013-2201-01 10 mg/10 mL vial (1 mg/mL), single vials.


NDC 0013-2202-01 20 mg/20 mL vial (1 mg/mL), single vials.






Single Dose Cytosafe™ Vials: Sterile single use only, contains no preservative.


NDC 0013-2576-91 5 mg/5 mL vial (1 mg/mL), single vials.


NDC 0013-2586-91 10 mg/10 mL vial (1 mg/mL), single vials.


NDC 0013-2596-91 20 mg/20 mL vial (1 mg/mL), single vials.


Store under refrigeration 2° to 8°C (36° to 46°F), and protect from light. Retain in carton until time of use.





REFERENCES


  1. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society. 1999: 32–41.

  2. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. Washington, DC; Division of Safety, Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health; 1992. US Department of Health and Human Services, Public Health Service Publication NIH 92–2621.

  3. AMA Council on Scientific Affairs. Guidelines for Handling Parenteral Antineoplastics. JAMA. 1985; 253: 1590–1591.

  4. National Study Commission on Cytotoxic Exposure - Recommendations for Handling Cytotoxic Agents. 1987. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.

  5. Clinical Oncological Society of Australia: Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia. 1983; 1:426–428.

  6. Jones RB, Frank R, Mass T. Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA Cancer J Clin.1983; 33: 258–263.

  7. American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm. 1990; 47:1033–1049.

  8. Controlling Occupational Exposure to Hazardous Drugs (OSHA Work-Practice Guidelines). Am J Health-Syst Pharm. 1996; 53: 1669–1685.


LAB-0131-2.0

January 2006



PRINCIPAL DISPLAY PANEL - 5 mg Vial Carton


5 mg


NDC 0013-2576-91


Rx only


5 mL Single-Dose CYTOSAFE® Vial


Idamycin PFS®

idarubicin hydrochloride

injection (1 mg/mL)


For IV use only


Sterile, Isotonic Solution


Pfizer Injectables




PRINCIPAL DISPLAY PANEL - 10 mg Vial Carton


10 mg


NDC 0013-2586-91


Rx only


10 mL Single-Dose CYTOSAFE® Vial


Idamycin PFS®

idarubicin hydrochloride

injection (1 mg/mL)


For IV use only


Sterile, Isotonic Solution


Pfizer Injectables




PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton


20 mg


NDC 0013-2596-91


Rx only


20 mL Single-Dose CYTOSAFE® Vial


Idamycin PFS®

idarubicin hydrochloride

injection (1 mg/mL)


For IV use only


Sterile, Isotonic Solution


Pfizer Injectables










Idamycin PFS 
idarubicin hydrochloride  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0013-2200
Route of AdministrationINTRAVENOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
idarubicin hydrochloride (idarubicin)idarubicin hydrochloride1 mg  in 1 mL










Inactive Ingredients
Ingredient NameStrength
Glycerin 
Water 
Hydrochloric Acid 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10013-2200-015 mL In 1 VIAL, SINGLE-USENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05073402/17/199706/01/2010







Idamycin PFS 
idarubicin hydrochloride  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0013-2201
Route of AdministrationINTRAVENOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
idarubicin hydrochloride (idarubicin)idarubicin hydrochloride1 mg  in 1 mL










Inactive Ingredients
Ingredient NameStrength
Glycerin 
Water 
Hydrochloric Acid 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10013-2201-0110 mL In 1 VIAL, SINGLE-USENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05073402/17/199706/01/2010







Idamycin PFS 
idarubicin hydrochloride  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0013-2202
Route of AdministrationINTRAVENOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
idarubicin hydrochloride (idarubicin)idarubicin hydrochloride1 mg  in 1 mL










Inactive Ingredients
Ingredient NameStrength
Glycerin 
Water 
Hydrochloric Acid 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10013-2202-0120 mL In 1 VIAL, SINGLE-USENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA05073402/17/199706/01/2010



Idamycin PFS 
idarubicin hydrochloride  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0013-2576
Route of AdministrationINTRAVENOUSDEA Schedule    







Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
idarubicin hydrochloride (idarubicin)idarubicin hydrochloride1 mg